JPMorgan says Novo’s Ozempic, Rybelsus inclusion in price negotiations expected

After the Centers for Medicare & Medicaid Services announced the selection of 15 additional drugs covered under Medicare Part D for price negotiations – including Novo Nordisk’s (NVO) Ozempic, Rybelsus, and Wegovy, GSK’s (GSK) Trelegy Ellipta, Pfizer’s (PFE) Xtandi, Bristol Myers’ (BMY) Pomalyst, Pfizer’s (PFE) Ibrance, AbbVie (ABBV) and Ironwood’s (IRWD) Linzess, AstraZeneca’s (AZN) Calquence, Teva’s (TEVA) Austedo, GSK and Theravance’s (TBPH) Breo Ellipta, Salix’s (BHC) Xifaxan, AbbVie’s Vraylar, Merck’s (MRK) Janumet, and Amgen’s (AMGN) Otezla – JPMorgan analyst Richard Vosser says the second list of price negotiation eligible drugs is in line with the firm’s expectations. The firm, which already factored in a 50% net price cut for the majority of these drugs in the Medicare Part D channel, most notably Ozempic and Rybelsus, adds that it assumes no Part D sales within its Wegovy forecasts as yet.